Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 672Carcinoma, Non-Small-Cell Lung 461Prostatic Neoplasms 391Neoplasms 383Lung Neoplasms 265Multiple Myeloma 249Colorectal Neoplasms 235Neoplasm Metastasis 216Melanoma 203Ovarian Neoplasms 166Leukemia, Myeloid, Acute 165Pancreatic Neoplasms 156Carcinoma, Renal Cell 142Squamous Cell Carcinoma of Head and Neck 141Lymphoma 137Brain Neoplasms 133Leukemia, Lymphocytic, Chronic, B-Cell 126Glioblastoma 126Recurrence 125Lymphoma, Non-Hodgkin 124Carcinoma, Hepatocellular 119Head and Neck Neoplasms 114Urinary Bladder Neoplasms 111Triple Negative Breast Neoplasms 110Stomach Neoplasms 109Precursor Cell Lymphoblastic Leukemia-Lymphoma 105Uterine Cervical Neoplasms 102Hematologic Neoplasms 99Lymphoma, Follicular 96Sarcoma 95

Interventions

tislelizumab 1teprotumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Insulin-Like Growth Factor I, Resistance To × 1 year × Clear all
NCT06866548 2025-12-04

Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Shanghai Changzheng Hospital

Phase EARLY_PHASE1 Active not recruiting
7 enrolled
Genitourinary

Insulin-Like Growth Factor I, Resistance To, Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡